# A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Source: https://onco.cc/trials/nct03611868/  
OnCo record `nct03611868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in melanoma and uveal melanoma, run by Ascentage Pharma Group Inc., active and no longer recruiting.

## Summary

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03611868 by Ascentage Pharma Group Inc., with 230 participants planned, started 2018-08-29 and due to reach its primary completion in 2025-12-30. Interventions recorded: Phase 1b: APG-115+pembrolizumab. Conditions listed: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03611868
- Phase: 1/2
- Setting: A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT03611868: https://clinicaltrials.gov/study/NCT03611868

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct03611868.json